GlassScriptPhysician profile
John A Fagan
NPI 1306904628
$7,504.83
in general payments reported to CMS, 2019-2025
71 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $61.21 · 2021: $668 · 2022: $916 · 2023: $1,616 · 2024: $1,314 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,504 · Consulting Fee: $150 · Entertainment: $21.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,504.00 |
| Consulting Fee | $150.00 |
| Entertainment | $21.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $840.92 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $666.07 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $492.28 | 2019-2025 | |
| Amgen INC. | $440.87 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $406.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $303.35 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $298.33 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Sumitomo Pharma America, INC. | $286.87 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $194.19 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Jazz Pharmaceuticals INC. | $190.95 | 2023-2025 | |
| Glaxosmithkline, LLC. | $179.62 | 2022-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $177.94 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $168.64 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $167.72 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $163.93 | 2019-2024 |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.